World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Immunology 55 3778 3482 154 145 217 15845

Sean Emery publications per year

The chart shows the history of publications by Sean Emery between 1977 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Sean Emery published across 49 years, from 1977 to 2025, averaging 4.7 papers a year. Output peaked at 17 publications in 2009. 3 of the 230 publications appeared in the last two years.

No. of publications
5 10 15
Bar chart. Horizontal axis: year, 1977 to 2025. Vertical axis: number of publications, 0 to 17. Peak 17 publications in 2009. 1977: 1 publication 1978: 1 publication 1979: 0 publications 1980: 0 publications 1981: 0 publications 1982: 0 publications 1983: 0 publications 1984: 0 publications 1985: 1 publication 1986: 1 publication 1987: 1 publication 1988: 1 publication 1989: 0 publications 1990: 1 publication 1991: 0 publications 1992: 0 publications 1993: 1 publication 1994: 0 publications 1995: 2 publications 1996: 3 publications 1997: 3 publications 1998: 3 publications 1999: 1 publication 2000: 7 publications 2001: 5 publications 2002: 4 publications 2003: 9 publications 2004: 5 publications 2005: 8 publications 2006: 13 publications 2007: 10 publications 2008: 9 publications 2009: 17 publications 2010: 16 publications 2011: 12 publications 2012: 9 publications 2013: 13 publications 2014: 7 publications 2015: 15 publications 2016: 13 publications 2017: 14 publications 2018: 9 publications 2019: 7 publications 2020: 1 publication 2021: 3 publications 2022: 0 publications 2023: 1 publication 2024: 2 publications 2025: 1 publication
1977 2025

230 publications in total across all disciplines

View publications per year as a table
Sean Emery: publications per year, 1977 to 2025
Year Publications
1977 1
1978 1
1979 0
1980 0
1981 0
1982 0
1983 0
1984 0
1985 1
1986 1
1987 1
1988 1
1989 0
1990 1
1991 0
1992 0
1993 1
1994 0
1995 2
1996 3
1997 3
1998 3
1999 1
2000 7
2001 5
2002 4
2003 9
2004 5
2005 8
2006 13
2007 10
2008 9
2009 17
2010 16
2011 12
2012 9
2013 13
2014 7
2015 15
2016 13
2017 14
2018 9
2019 7
2020 1
2021 3
2022 0
2023 1
2024 2
2025 1
Total 230
Download as CSV

Sean Emery publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Sean Emery sits on this spectrum.

No. of scientists
50 100 150
Bar chart with 76 bars. Horizontal axis: publications, 62–71 to 807+. Vertical axis: number of scientists, 0 to 189. Most scientists, 189, have 152–161 publications. The last bar groups every scientist with 807 publications or more. The highlighted bar, 212–221 publications, is where this scientist sits. 62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientist 807+ publications: 100 scientists
62–71 publications 807+

This scientist: 217 publications — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

View publications distribution as a table
Number of Immunology scientists by publication count, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
Publications Scientists This scientist
62–71 9
72–81 23
82–91 40
92–101 72
102–111 86
112–121 108
122–131 150
132–141 160
142–151 159
152–161 189
162–171 166
172–181 181
182–191 188
192–201 187
202–211 178
212–221 158 217
222–231 168
232–241 159
242–251 160
252–261 148
262–271 116
272–281 125
282–291 115
292–301 111
302–311 95
312–321 97
322–331 97
332–341 99
342–351 96
352–361 69
362–371 76
372–381 71
382–391 71
392–401 62
402–411 54
412–421 41
422–431 63
432–441 53
442–451 31
452–461 42
462–471 40
472–481 29
482–491 34
492–501 30
502–511 23
512–521 41
522–531 29
532–541 28
542–551 16
552–561 18
562–571 18
572–581 17
582–591 17
592–601 17
602–611 19
612–621 13
622–631 12
632–641 11
642–651 16
652–661 9
662–671 5
672–681 13
682–691 12
692–701 6
702–711 6
712–721 9
722–731 9
732–741 6
742–751 11
752–761 10
762–771 7
772–781 12
782–791 7
792–801 5
802–806 1
807+ 100
Download as CSV

Sean Emery D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Sean Emery sits on this spectrum.

No. of scientists
50 100 150 200
Bar chart with 60 bars. Horizontal axis: D-Index, 40–41 to 157+. Vertical axis: number of scientists, 0 to 201. Most scientists, 201, have 58–59 D-Index. The last bar groups every scientist with 157 D-Index or more. The highlighted bar, 54–55 D-Index, is where this scientist sits. 40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40–41 D-Index 157+

This scientist: 55 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

View D-Index distribution as a table
Number of Immunology scientists by D-index, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
D-Index Scientists This scientist
40–41 28
42–43 91
44–45 157
46–47 192
48–49 175
50–51 188
52–53 177
54–55 155 55
56–57 194
58–59 201
60–61 197
62–63 201
64–65 173
66–67 167
68–69 172
70–71 199
72–73 184
74–75 133
76–77 163
78–79 127
80–81 121
82–83 125
84–85 121
86–87 102
88–89 96
90–91 75
92–93 72
94–95 74
96–97 66
98–99 68
100–101 49
102–103 60
104–105 54
106–107 36
108–109 23
110–111 52
112–113 41
114–115 34
116–117 25
118–119 28
120–121 11
122–123 20
124–125 27
126–127 19
128–129 20
130–131 16
132–133 17
134–135 14
136–137 15
138–139 9
140–141 11
142–143 9
144–145 9
146–147 7
148–149 7
150–151 7
152–153 5
154–155 8
156 6
157+ 96
Download as CSV

Overview

Sean Emery is affiliated with the University of New South Wales in Australia. Their primary research field is Medicine, with a focus on several subfields including Infectious Diseases, Epidemiology, Virology, Emergency Medicine, and Cardiology and Cardiovascular Medicine. The majority of their work concentrates on topics related to HIV/AIDS drug development and treatment, Pneumocystis jirovecii pneumonia detection and treatment, HIV/AIDS research and interventions, and various aspects of fungal infections and antifungal resistance.

The scientist has contributed to notable recent research papers, including:

  • "Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability" (2021, Immunity)
  • "Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection" (2023, NEJM Evidence)
  • "Epidemiology of candidemia in NICE area, France: A five-year study of antifungal susceptibility and mortality" (2021, Journal de Mycologie Médicale)
  • "Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial" (2024, The Lancet HIV)
  • "2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings" (2021, Journal of Antimicrobial Chemotherapy)

Frequent coauthors collaborating on research with Sean Emery include Anthony D. Kelleher, Nnakelu Eriobu, Anchalee Avihingsanon, Marcelo Losso, and Sounkalo Dao.

The scientist's research has been published in a range of venues, with multiple works appearing in journals such as Immunity, The Lancet HIV, NEJM Evidence, Journal de Mycologie Médicale, and Journal of Antimicrobial Chemotherapy.

Sean Emery's work spans diverse aspects of infectious diseases, particularly focusing on HIV/AIDS and fungal infections. Their research addresses the development and evaluation of antiretroviral therapies, the epidemiology and treatment of fungal infections like candidemia and Pneumocystis jirovecii pneumonia, and the prediction of treatment response in HIV care. This body of work contributes to multiple areas within medicine and infectious disease research.

Best Publications

  • Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

    Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka

  • CD4+ count-guided interruption of antiretroviral treatment.

    Wafaa El-Sadr;Wafaa El-Sadr;Jens D Lundgren;James Neaton;Fred Gordin

  • Initiation of antiretroviral therapy in early asymptomatic HIV infection

    Sean Emery;Shweta Sharma;Gerd Fätkenheuer;Josep M. Llibre

  • Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection

    Netanya Sandler;Handan Wand;Annelys Roque;Matthew G Law

  • Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study

    Sean Emery;Jacqueline A. Neuhaus;Andrew N. Phillips;Abdel Babiker

  • Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study

    Benjamin R Bavinton;Angie N Pinto;Nittaya Phanuphak;Beatriz Grinsztejn

  • Interleukin-2 therapy in patients with HIV infection.

    D. Abrams;Y. Lévy;M. H. Losso;A. Babiker

  • Prevalence of Metabolic Syndrome in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy Using International Diabetes Foundation and Adult Treatment Panel III Criteria: Associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia

    Katherine Samaras;Handan Wand;Matthew Law;Sean Emery

  • Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.

    Allison Martin;Don E Smith;Andrew Carr;Clare Ringland

  • Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: A Randomized, 96-Week Trial

    Allison Martin;Mark Bloch;Janaki Amin;David Baker

  • No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial

    Andrew Carr;Cassy Workman;Dianne Carey;Gary Rogers

  • HIV lipodystrophy: prevalence, severity and correlates of risk in Australia.

    J Miller;A Carr;S Emery;M Law

  • Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4+ cell counts and HIV RNA levels during follow-up

    Jens D. Lundgren;Abdel Babiker;Wafaa El-Sadr;Sean Emery

  • Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.

    Handan Wand;Alexandra Calmy;Dianne L Carey;Katherine Samaras

  • Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

    John M Murray;Sean Emery;Anthony D Kelleher;Matthew Law

  • Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.

    Mark A Boyd;N Kumarasamy;Cecilia L Moore

  • In Vivo, Nucleoside Reverse-Transcriptase Inhibitors Alter Expression of Both Mitochondrial and Lipid Metabolism Genes in the Absence of Depletion of Mitochondrial DNA

    Patrick W. G. Mallon;Patrick Unemori;Rebecca Sedwell;Adrienne Morey

  • High Levels of Human Antigen-Specific CD4+ T Cells in Peripheral Blood Revealed by Stimulated Coexpression of CD25 and CD134 (OX40)

    John J. Zaunders;Mee Ling Munier;Nabila Seddiki;Sarah Pett

  • Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.

    Rebekah L. Puls;Janaki Amin;Marcelo Losso;Praphan Phanuphak

  • Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: A randomized trial

    W M El-Sadr;B Grund;J Neuhaus

  • Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study

    Abdel G Babiker;Sean Emery;Gerd Fätkenheuer;Fred M Gordin

  • Pooled Analysis of 3 Randomized, Controlled Trials of Interleukin-2 Therapy in Adult Human Immunodeficiency Virus Type 1 Disease

    S. Emery;W. B. Capra;D. A. Cooper;R. T. Mitsuyasu

  • Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study

    Dianne Carey;Rebekah Puls;Janaki Amin

  • Does Choice of Combination Antiretroviral Therapy (cART) Alter Changes in Cerebral Function Testing after 48 Weeks in Treatment-Naive, HIV-1–Infected Individuals Commencing cART? A Randomized, Controlled Study

    Alan Winston;Chris Duncombe;Patrick C. K. Li;John M. Gill

  • Minor changes in calculated creatinine clearance and anion‐gap are associated with tenofovir disoproxil fumarate‐containing highly active antiretroviral therapy

    A Winston;J Amin;Pwg Mallon;Pwg Mallon;D Marriott

  • Outpatient Continuous Intravenous Interleukin-2 or Subcutaneous, Polyethylene Glycol—Modified Interleukin-2 in Human Immunodeficiency Virus—Infected Patients: A Randomized, Controlled, Multicenter Study

    Andrew Carr;Sean Emery;Andrew Lloyd;Jennifer Hoy

Frequent Co-Authors

David A. Cooper
David A. Cooper University of New South Wales
Anthony D. Kelleher
Anthony D. Kelleher University of New South Wales
Janaki Amin
Janaki Amin Macquarie University
Andrew Carr
Andrew Carr University of Oxford
Matthew Law
Matthew Law University of New South Wales
James D. Neaton
James D. Neaton University of Minnesota
Jens D. Lundgren
Jens D. Lundgren Rigshospitalet
Jennifer F Hoy
Jennifer F Hoy Monash University
Kiat Ruxrungtham
Kiat Ruxrungtham Chulalongkorn University
Stephen J. Kent
Stephen J. Kent University of Melbourne

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying immunology opens doors to diverse healthcare careers, many of which can be supported by complementary online degree programs. For those interested in advancing clinical skills quickly, accelerated NP programs online offer a fast track to becoming nurse practitioners specializing in immunology-related fields.

Individuals without a nursing background can also explore online nursing programs for non nurses designed to build foundational knowledge and clinical skills from the ground up. These programs often lead to licensure and can be stepping stones toward more advanced immunology careers.

For a quicker entry into nursing, many consider accelerated BSN programs for non nurses, which provide an efficient pathway from a non-nursing background to becoming a registered nurse. This can be critical for those aiming to work in immunology labs or patient care in related specialties.

Additionally, accredited LPN programs easy to get into offer accessible routes for entry-level nursing roles. These positions are valuable for gaining practical experience in immunology-focused healthcare settings and can serve as a foundation for future academic and career advancements.

Best Scientists Citing Sean Emery

Trending Scientists

Recently Published Articles